Mirai Bio offers end-to-end development capabilities for biopharmaceuticals, utilizing advanced bioprocessing techniques to streamline product development. The company addresses inefficiencies in the drug development pipeline, enabling faster time-to-market and reduced costs for biotech firms.
Funding
$120M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The development of genetic medicines is often hampered by inefficiencies in cargo design, targeted delivery to specific tissues and cell types, and scalable manufacturing processes. These challenges can lead to prolonged development timelines and increased costs for biotech companies.
Solution
Mirai Bio offers an end-to-end platform designed to optimize and accelerate the development of genetic medicines, from initial concept to clinical application. The platform leverages machine learning for generative design of optimized cargo and delivery vehicles. It also employs high-throughput in vivo multiplexing to generate data for chemistry, formulation, and cargo composition. Mirai's approach co-optimizes design, delivery, and manufacturing, ensuring the best possible formulation and manufacturing strategy for each medicine. By integrating these capabilities, Mirai Bio enables biotech companies to focus on validating therapies while streamlining the overall development process.
Target Audience
Mirai Bio primarily serves biotech companies seeking to optimize performance and accelerate the translation of genetic medicines from concept to clinic.
Features
- Machine-learning models for generative design of cargo and delivery vehicles
- High-throughput in vivo multiplexing for rapid data generation and analysis
- Co-optimization of design, delivery, and manufacturing processes
- Access to end-to-end development capabilities with innovation at every step
- Focus on unlocking delivery of genetic medicines to any tissue and any cell type
- Streamlined translation of drug development from research through commercialization